| PD-1/PD-L1在非小细胞肺癌中的临床研究进展 |
| |
| 引用本文： | 杨德松,苏敏,王文祥. PD-1/PD-L1在非小细胞肺癌中的临床研究进展[J]. 中国肿瘤临床, 2017, 44(14): 726-730. DOI: 10.3969/j.issn.1000-8179.2017.14.159 |
| |
| 作者姓名： | 杨德松 苏敏 王文祥 |
| |
| 作者单位： | 湖南省肿瘤医院，中南大学湘雅医学院附属肿瘤医院胸外二科（长沙市 410013） |
| |
| 摘 要： | 近年来，免疫治疗在癌症研究中取得了突飞猛进的发展。以程序性死亡受体-1（programmed cell death-1，PD-1）及其配体程序性死亡配体-1（programmed cell death-ligand 1，PD-L1）为靶点的免疫治疗药物在非小细胞肺癌（non-small cell lung cancer，NSCLC）的治疗中显示出了良好的疗效和耐受性，治疗前景值得期待。本文对PD-1/PD-L1治疗NSCLC的临床研究现状进行综述。
|
| 关 键 词： | 免疫治疗 程序性死亡受体-1 程序性死亡配体-1 非小细胞肺癌 |
| 收稿时间： | 2017-02-13 |
Research progress on PD-1/PD-L1 in the treatment of non-small cell lung cancer |
| |
| Desong YANG,Min SU,Wenxiang WANG. Research progress on PD-1/PD-L1 in the treatment of non-small cell lung cancer[J]. Chinese Journal of Clinical Oncology, 2017, 44(14): 726-730. DOI: 10.3969/j.issn.1000-8179.2017.14.159 |
| |
| Authors: | Desong YANG Min SU Wenxiang WANG |
| |
| Affiliation: | Second Department of Thoracic Surgery, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China |
| |
| Abstract: | In recent years, immune therapy for the treatment of cancer has made remarkable progress. The monoclonal antibodies of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) have shown considerable responses and good tolerance in the treatment of non-small cell lung cancer (NSCLC). In this review, we summarized the current clinical status and future direction of PD-1/PD-L1 in NSCLC. |
| |
| Keywords: | immune therapy programmed death-1 programmed death-ligand 1 non-small cell lung cancer |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
